[{"id":"701870c6-cbbc-4e3e-a80e-76fa0fa4ed41","acronym":"DRAGON","url":"https://clinicaltrials.gov/study/NCT04291079","created_at":"2021-01-18T20:49:29.388Z","updated_at":"2024-07-02T16:35:23.706Z","phase":"Phase 1","brief_title":"SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)","source_id_and_acronym":"NCT04291079 - DRAGON","lead_sponsor":"Scholar Rock, Inc.","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e linavonkibart (SRK-181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-11"}]